Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder, affects over 55 million people globally along with an increasing burden of about 10 million new cases every year and costs the world economy around US$ 1.3 trillion annually, reported by the World Health Organization (W.H.O.) [1]. Despite decades of research, effective disease-modifying treatments have remained elusive. However, a new generation of therapeutic strategies is now reshaping the treatment landscape, giving renewed hope to millions of families worldwide [2].
The Current Landscape: Limited but Landmark Therapies
Until the recent past, the clinical management of Alzheimer’s disease (AD) relied largely on symptomatic treatment [1][2]. Drugs including cholinesterase inhibitors (donepezil, galantamine) and NMDA receptor antagonists (memantine) have been routinely prescribed to offer modest, short-term improvements in cognition. These drugs, however, fall short of modifying the underlying neurodegenerative processes that characterize the disease.
A turning point was reached in 2021 with the conditional approval of aducanumab, soon followed by the Food and Drug Administration (FDA) approval of lecanemab (Leqembi) in 2023 [2][3][4]. Lecanemab, a monoclonal antibody that targets amyloid-beta protofibrils, exhibited a 27% reduction in cognitive decline among patients with early-stage AD in the landmark Clarity AD trial. Approved in the U.S.A., Japan, and China, lecanemab represents a landmark step in disease-modifying therapy. To enhance accessibility, a subcutaneous formulation is also under fast-track regulatory review.
Despite their promise, these therapies are associated with critical caveats. The application of these therapies is restricted to narrowly defined populations – those with biomarker-confirmed amyloid pathology, and they carry potential adverse effects, including amyloid-related imaging abnormalities (ARIA). Moreover, the cost also remains a barrier, with annual treatment expenses ranging from $26,500 to $32,000 [5].
Why Have So Many Drugs Failed?
Despite recent breakthroughs, the search for effective Alzheimer’s treatments has been riddled with failures. Between 2000 and 2020, 99.6% of the drugs tested failed to gain approval, with only five eventually approved, providing only short-term symptom relief [2][6].
Several structural barriers underlie this strikingly low success rate. Late-stage diagnosis remains a major obstacle, with most patients identified only after extensive and irreversible neuronal damage has occurred. The biological complexity of the disease, ranging from amyloid and tau pathology, neuroinflammation, mitochondrial dysfunction, and immune dysregulation, precludes it from being effectively targeted with a single mechanism of action [2][7]. Compounding this are protracted clinical timelines, with development durations averaging over 12 years for biologics and almost 10 years for small molecules.
New Tools, New Hope: Enhancing Diagnosis and Drug Discovery
One of the most promising advances in recent years has been the drift toward earlier and precision diagnosis. The AT(N) framework, dividing pathology into Amyloid, Tau, and Neurodegeneration, has enabled clinicians to identify biological indicators of the disease long before the manifestation of symptoms [8]. This progress is supported by the emergence of blood-based biomarkers such as Aβ42/40 and phosphorylated tau (p-tau181), along with digital pathology tools powered by artificial intelligence, including deep learning algorithms trained to identify tauopathy from pathology slides [9][10].
Platforms like the Agora evidence integration tool and the SEA-AD single-cell atlas are further accelerating therapeutic developments by uncovering new cellular and molecular targets [11][12].
Pipeline of Promise: From Monotherapy to Multimodal
The Alzheimer’s drug development landscape includes 164 clinical trials investigating 127 therapeutic agents, according to the Cummings and colleagues' 2024 pipeline analysis [2]. These include 48 are in Phase III, 90 in Phase II, and 26 in Phase I trials. Targets span across amyloid (23%), tau (14%), neuroinflammation (13%), synaptic plasticity (12%), and bioenergetics.
Among anti-amyloid therapies, donanemab and gantenerumab are in late-stage trials, extending the precedent set by aducanumab and lecanemab [2]. Tau-targeted agents like E2814...
(All Rights Reserved)